AstraZeneca PLC (AZN)vsLive Ventures Inc (LIVE)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
LIVE
Live Ventures Inc
$13.25
+0.61%
CONSUMER CYCLICAL · Cap: $40.70M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13575% more annual revenue ($60.44B vs $441.98M). AZN leads profitability with a 17.2% profit margin vs 5.0%. LIVE trades at a lower P/E of 2.8x. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
LIVE
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+89.0%
Fair Value
$177.00
Current Price
$13.25
$163.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 26 in profit
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
5.0% margin — thin
Operating margin of 3.2%
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : LIVE
The strongest argument for LIVE centers on P/E Ratio, Price/Book, Return on Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : LIVE
The primary concerns for LIVE are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while LIVE is a value play — different risk/reward profiles.
LIVE carries more volatility with a beta of 1.06 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 44/100), backed by strong 17.2% margins and 12.5% revenue growth. LIVE offers better value entry with a 89.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Live Ventures Inc
CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA
Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?